News headlines about SteadyMed (NASDAQ:STDY) have been trending positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SteadyMed earned a coverage optimism score of 0.44 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.1625587187764 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Separately, Zacks Investment Research upgraded SteadyMed from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th.
Shares of SteadyMed (STDY) traded down 1.61% during midday trading on Tuesday, hitting $6.10. The stock had a trading volume of 10,595 shares. SteadyMed has a 52 week low of $2.25 and a 52 week high of $9.70. The company’s 50 day moving average is $6.49 and its 200 day moving average is $5.43. The firm’s market cap is $153.54 million.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/08/08/steadymed-stdy-receiving-positive-news-coverage-report-finds.html.
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).
Receive News & Ratings for SteadyMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.